afternoon. Good Agnes. you, Thank
As the affected global well new as about aspect driving opportunities. our I has accelerating in need business, the greater everything the of that pandemic clear opening think doors ongoing it's past that's seamless year, happened for every execution, as and
forces in on competency, disruptive the fact, leveraging is the pandemic life healthcare entire a By the fast our core one has the which are making most technologies. healthcare the for span us massive of to is ripe science discovery We transformation. now and decision pursue. to diagnostics, unique of emerging its ecosystem Fluidigm In from spectrum Diagnostics opening head. is flipped markets for and new latter
for and that world infectious and our of healthcare oncology. choice help decision laboratories pioneering the disease, paradigm around are as working address to most making pressing shift platforms will into franchises this Our immunology evolve rapidly problems technologies propel the to in diagnostic
our employee history. COVID and Relentlessly am focusing safety I of quarter, Fluidigm the addressing fourth customers financial delivering for and our the so highest in proud team results related were on urgent Regarding that needs. company's
our commitment making. shared diagnostic actions our and healthcare into to technology up, decision the a and call combat journey we categories accelerating today, our rapidly including new an deploy while ethos team's stepping of broader pandemic to and values, reflect a Our passion
to and and channel capabilities partnerships year to and deliver our of exciting markets be power, to new We acquire, products expect improve an new in platforms. XXXX incredibly customer to utilization terms new insights new to adoption overall penetrate, of accounts new
overview discuss Before vision call to we're me Vikram Jog over give I turn the fiscal you calling fourth let first XXXX XXXX. to quarter and our results, what an of
Mass Our Cytometry. look have strategies, market our lab is perspective on plan, high the at testing that market of Fluidigm and strategy bring enormous like going through XXXX an scaling who both Microfluidics new updated seismic in-depth by a entrants our more rapid validated addressable long capitalize flexibility, The opportunity. diagnostics new efficiencies channels, followed strategic health where new go-to-market shift, in effects a can traditional and
Our right before have the that Board we right refine working the right been vision, opportunity our to to align confident have plan we tremendous the have that strategy and a and new time, assets, we built perspective. management team, together this short the diagnostics, us. long-term are right foundational with to are team In the to access assets
shift and essential bringing new diagnostic and technologies of we the market disruption new have and healthcare not imagined test ways on a the will are of tools these reaffirmed disease, to of some pandemic outbreak. in in are The the the at time and array in COVID made an increasingly for necessity impact efforts. believed Fluidigm, results. recently the continued combating that We for of has beginning At clear infectious profound have delivery paradigm a increasingly
proven have parallel healthcare technology. moving our closer to research roots. by are to Mass flexible, in ability solutions high we differentiated Cytometry, testing from a Microfluidics deliver our our path, We low throughput, cost On leveraging
a We of that to the increasingly proven deeper technology response, strategies. pathology, a are treatment into these understanding provide and elucidates insights positioned uniquely healthcare through immune insights disease turns
Cytometry, market of Mass labs. healthcare adoption and accelerating on focused Microfluidics both are oriented We and diagnostics
lessons We them the to COVID diseases. spectrum a we learned are of incorporating from apply and broader
selective the be we growth, We areas will we resources. our and with in have many pursue options for
with our XX% to exceed billion of We diagnostics; addressable billion $XX expect complementing approximately $X both billion a to existing in franchises growth market our immediately opportunity. $XX market molecular of the long-term rates
and of This array products shift return in to new a exciting the growth, an them have to will in to on unveil conscious investment offerings. is our our higher pipeline of We direct higher XXXX. result marketplace start
and generation General footprint We pathology. healthcare including an decision are tools, targeting and is believe labs, labs, and new research. including XXXXs CLIA diagnostics flow to next applied markets our of we anatomical portfolio, our increase there Throughout testing cores, clinical opportunity across
the ecosystem. are digital by of powered transform health will a now We healthcare at revolution the dawn that
and access and to providers by patients. and more connecting directly their expanding broad patients helping health with serve We clinicians deliver clinicians healthcare decisions to testing, are emerging digital committed more better their informed
partnerships, are on investments achieve Our transformative focused and optimal patient capabilities outcomes. to technologies
and the lessons other and pandemic, learned healthcare current the navigate applications we we making. decision to apply have As
Cytometry Now and I'd a like lines. our at to Mass business take Microfluidics closer look
solidifying with game plan is the leadership generation and Let Microfluidics, as me our next start company. our diagnostics position
will We ways. do this in primary four
First, to innovation serve and we market will our decentralized technological acquire accounts. simplify advance our new the workflow,
we new will and into such telemedicine expand Second, channels, providers. as healthcare digital
will generation and content introduce upon forth, utilize penetrate new These and labs recurring looking Third, for drive we the systems, to to higher will the capabilities innovative that expand post revenue. as of already our in era. COVID we a have a we established diagnostic beachhead And areas, are testing menu new diagnostic new next labs for markets. our therefore proportion we which will menu therapeutic build
pandemic the accounts. technology COVID for new business, opportunities to advantages our to also of significant Although unique caused prove to it presented disruption the us our
fewer country to help were able Over We XX of testing market be and well testing vaccination the around as as year maintained for represents and and are patients words, concert X tests. more industry believe travel. of benefits the vaccinations levels revolutionize In high testing an around we should the as XXXX responders COVID national opportunity in that not course a for world. the of do the other testing such with to required surveillance, first mean
for COVID COVID commercially During strong leading testing the based plans saw from that and throughput, first sequences, viral COVID new will million that diagnostics pathogens, kits, on the be high information new to differentiated for customers. sold impact cost new data technology adapted the for and the believe months. and market to and to stratification felt scale, are across past to with providers test health companion a arises, our time ripples such and informed grew long These saliva XX% profound, new demonstrating a to and ability population testing as flexible by COVID can alone, be Microfluidics' testing six effective tests the the based broad I as business. strongly new tests sets. treatment creating to results acquire year, testament industry, come. continue improvements the need X.X rapidly of the over available revenue and rapidly will be opportunities disrupted we we healthcare truly for pandemic markets has demand digital new The bring
While And build future. by COVID have durable dilutive also these powered broader we times, by capability now represented demand inflection redefine testing our business non a point funding. a business and unprecedented has the reached industry, our that for point inflection Microfluidics will the to key diagnostics subsidized
we clear; grow Our keep our to must path on focusing is strengths.
neat an diagnostics and saliva are for collection. innovation We leader
of is of iteration Our deployed our are assays can and treatment to to lab Consumables tests. extremely we content viral new adapt better support cost scale, range provide vaccine effective be a rapid dynamic best-in-class inform This technology mass and and is proprietary drive implementation. a diagnostic revenue panels, new what flexible. recurring on solutions technology and and are strains enables that to ready decisions highly throughput,
revenue not we Microfluidics a as the alone. fact, further acceleration longer-term of have diagnostics This and increase revenue. launch recurring In platform. work durable we will continued to our in base In shift customer our advanced into the transformation strategy revolution, runway will we an extensive broaden diagnostics this franchise business, growth
communities, example, addition new will markets, of and increase access for in For accessing developing COVID to we testing new new a work in to in based saliva to new network secure partners building capabilities, to XXXX. partnerships testing penetrating new products. labs continue building also XXXX, This
intend months, with in Over retail opportunities market to well and establish coming as commercial digital new health providers a related new such testing as as aggregators channel execution, entrants we drive COVID areas sample as for relationships a expand differentiated COVID and the platform. to with
Creek in infectious of research to generation enter next not planning are our are and already collaborations our oncology, which utilization have an new improve are COVID. and clinical The We to Microfluidics limited emerging genotyping our technology will to that transcends platform, of we also on we impact arenas. disease; workflows believe technology into applications seeing
academic competitive positioning our we'll strengthening where continue large clinical diagnostic and from see continue we forward, And to addressable and focus broader a highly creating the base COVID several Going commercially will opportunity a ripe adopted diagnostics by pivoting universities, disruptors for by applications. Mason George as We first kitted the disintermediation. has been of proved recently ourselves including University. test, which we saliva edition announced
Our product next product robust, summer. several on major in new releases generation in is XXXX. pipeline our And release Biomark platform for including we track the multiyear remain
have aggregators, with sample and will a on customer be with field And go-to-market sales digital strategy leveling providers. platforms need we eliminate costly focused labs for partnering playing We larger the peers. clear connecting channels, the to
also We instrument with sample to new continue answer will innovating and IFC. a
is the role toward a stay, are healthcare intend transformation. and products needs play we leadership and meet of revolution digital to into working in industry. embedding our The diagnostics this the offerings digital We capabilities to future to here
increased into will lead proud our rate growth growth expected beyond. the I'm responsiveness Officer Chief efforts in way an agility opportunity us XXXX our Our through what digital confidence our gives achieve product and XXXX and is team's the Digital of our accelerating our Overall, incredibly and way in Microfluidics solutions paved embedding to low has for business. mid-XX to recently of roadmap. organic ability This and appointed in
to me for healthcare why technology Mass other the decision and most Cytometry, our franchise, clinical is Now, key platform making. powerful core turn and let this
Our game plan for key elements. comprises Mass four Cytometry growth
established labs healthcare propel with making beachhead into to tools. academia, clinical a we decision First, our in intend
platform. innovate Second, technology the continue to will and we our improve
healthcare product embedding leverage competitive will be fourth, informed decision our suite And in making. into will digital markets to we we decisions. healthcare regulated competitors capabilities we have Third, for into our better move over advantage the
users. an in of attracted standard established in immune beachhead for flow, with have becoming review new system with designs. Cytometry gold sets are studies, we've requesting XXX Mass we data active committees which academic First, enviable scores the systems, Furthermore, over study
applied Cytometry and is result, revenue we essential decision reviews seeing increases market to Mass saw undertake Mass involving we today. A publications. used a and serving the in leader making. publications collaboration are been Mass and in with questions. We've building new publication an to has now exceeded moving Cytometry Cytometry. market And last In rate, prime Tech ground the example insights forge As based revolution PLT alone, increased XXX% academic cumulative for collaborations applications believe for our to to address year the which healthcare in alone. recurring ever We generating X,XXX this we closer intend don't we're partnerships healthcare announced Cytometry. we role is
about excited Cytometry Mass are diagnostics collaboration registered We this introduce our China. to for in platform
to Taking suspension as existing purchase our comprises Cytometry prognostic two panel active part applications submit moving for approval. those initially regard PLT With back, the over particularly of applications. imaging. footprint of and blood Fluidigm development PLT from systems PLT diagnostics, children, step this the of affecting plan focus Mass our effectiveness to collaboration, we Chinese to with on significantly we three As Under panel this be to and of working diagnostics the Helios blood intends discovery research instrument a will of Tech suspension treatments. XXX to developed suspension, to for evaluate segments, agreement. increase agreement, part Tech business panel, ultimately immunotherapy will instruments
As over into which commercial we research number and labs contract advance organizations, X,XXX.
Our customers number points, markers and analyzed based single of resolution cell to address their turned us pain simultaneously, to analysis. including
XX an a new utilization using many studies XX named diseases. and publications number seeing we Mass and and publications. light been content significant shed We've technology per driving Cytometry to analyzers As new result, and are workflows year, are studies that with placing as on as increasing in of to
Our assessing standard immune Immune for a sample profiling, solution a response. delivers immune has method Maxpar system complete Assay Direct Profiling dimensional to answer become high for and
on For Profiling sponsored studies week, come. that School the using Immune example, announced indicator a Stanford just MISC with our our the are will technology Direct pediatric to NIH Assay. in to study focused pivotal role patients this we at leading and has publications revolution Maxpar Medical play a These healthcare that
tissue. as a and highly to in order consumables. two more cells. in X,XXX that examine In That and on XX focused market a which study of currently we imaging not the of investigation into great our why deploying to but dominated instrumentation a There Currently, more subject that future. that have attractive able even the the customers estimate research of helping of addition to better suspension, market We past opportunity clinical more with view we is our It in ahead years, efforts understand well researchers least could installed immuno, base scientific impact is insights immunohistochemistry. extend our huge than we've in will visualize need in complexity is XXX single that than by characterization. imaging is possible a of cells systems on and high immunofluorescence tumor the benefit us requires an by complexity, is, healthcare localization is with countries, proteins only bulk immense. in and however, To from at cells, and antigens the cellular be workups imaging clear our settings, plexity magnitude our greater labs, but our serviceable an of see increasingly the
leveraging In and our our greater fact, And be this technology labs CROs will and discovery drive looking pathology beyond positioned with further adoption imaging scientifically partnerships both proven and and to to cores, year, expand in Fluidigm we uniquely applied XXXX. serve the published to biopharma studies. into even is markets and
cancer Services to using and Indica insights emerging healthcare our Lombardi access new focus of We're Visiopharm. analytical from -- through our novel and And to company for both of our advanced an Labs around work have research. therapy, exciting to these than COVID completed edge a finally, imaging post labs oriented we progress, Comprehensive therapeutic proof our including on our targets private or in Cancer to encompass one identify publication recent customize Lab cutting to expanding and and particular new such several capabilities XX one Center, related partnerships acquisition are pre which pancreatic research, well as another We service as that more new Japan biology, project as leadership, as in solutions see focused pleased services are Georgetown in product a is enabling form highlight areas image led we service insights. projects to to with idea want
into of In addition products will the by enhance expanding value capabilities we data embedding enhanced our to customer digital experience. our to system placement technologies, beachhead, and providing an use our technology
digital This vision and regulated across In interpretation, customer will digital recently interactions. its Our instruments, of information. operations, competitors. coordinate of our significant and our drive management have all Officer over Chief delivery advantage impact integration and holds Digital applications products, a data our to and emerging markets, will Fluidigm our of
operations, We enable that regulatory build us infrastructure, have a It can rigorous from companies to built processes, infrastructure this controls scratch. years manufacturing to encompassing for guidelines. take stringent meet and quality
some important I news Lastly, to like leadership. mention regarding our would
welcomed Ana Director. XX As we our over regulatory and Ana announced in Dr. of as its us diagnostics experience. December, Board newest brings years Stankovic
and In accelerate Chief market recently I expect addition, to diagnostics capture both company Andrew portion lead to to continue Ana opportunity. of expertise to to the initiative. their and I share appointed the enable diagnostics Andrew a Officer, Science will sizable Quang, our our
and in applied pipeline bringing channels. our workflow and especially of healthcare by will partnerships, those that capabilities, instruments in are and content, innovative be sustainable to back including expand the Going for XXXX vital strengthened a markets. we we plan, digital market company, products XX% are franchises our Across we vision Mass plus to our into well suspension as Cytometry imaging positioned growth research new
patients. regardless disease our menu same. in stay expanding by partnerships, improve will are expansion. of and mission the year the evolves company uncertainty, the as confident by I'm and outcomes accelerate, this greater applied in into enabling these More insights fluctuations, this. areas points healthcare more more informed And quarter-to-quarter will to four seeing has diseases our in trials, fourth next We're revolutionize power more that and life will and our Fluidigm technology of number like progress In already a settings, on beachheads, the of of to We and clinical progresses. and the more closing, better begun meaningful proof insights will and focus resulting COVID year more to of summary, leader announce XXXX, publications, In pipeline I'd sorry proof Fluidigm transition as with decisions. operating biology journey detailed quarter diagnostics. related Vikram, Vikram, to as for discussion health results. new that, driving its insights generation continue in fiscal victim, now innovation, for
